New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
15:11 EDTABTEarnings Preview: Abbott's Q4 will be last to include proprietary pharma
Abbott Laboratories (ABT) is scheduled to report Q4 earnings before the market open on Wednesday January 23, with a conference call scheduled for 9:00 am ET. Abbott is engaged in the discovery, development, manufacture, and sale of health care products worldwide. The company recently separated its proprietary pharmaceutical business into AbbVie, an independent company... EXPECTATIONS: Analysts are looking for EPS of $1.50 on revenue of $10.58B, according to First Call. The consensus range for EPS is $1.47-$1.53 on revenue of $10.40B-$10.76B... LAST QUARTER: Abbott reported Q3 EPS of $1.30 against estimates of $1.28 on revenue of $9.77B against estimates of $9.93B. On its Q3 earnings conference call the company said it was too early to give FY13 guidance... STREET RESEARCH: On January 11, Barclays initiated Abbott with an Equal Weight and a $35 price target. Earlier in January, Deutsche Bank downgraded Abbott to Hold from Buy with a $33 price target citing valuation following the spin-off of AbbVie, while Wells Fargo in a research note on January 2 said Abbott shares are attractive following the spin-off, citing significant margin expansion opportunities. Wells Fargo gave a valuation range on Abbott shares of $33-$34 to reflect the spin-off... PRICE ACTION: Shares of Abbott traded in an upward trajectory in 2012 from approximately $56.50 to a high of approximately $72 reached in mid-October. Abbott has traded in a range of approximately $31.64 to $33.88 since the company announced the completion of the spin-off on January 2.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
10:00 EDTABTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMC Networks (AMCX) upgraded to Buy from Hold at ISI Group... Abbott (ABT) upgraded to Buy from Hold at Deutsche Bank... Ahold (AHONY) upgraded to Overweight from Neutral at JPMorgan... Alere (ALR) upgraded to Buy from Hold at Craig-Hallum... Ambev (ABEV) upgraded to Buy from Neutral at Goldman... Bayer (BAYRY) upgraded to Outperform from Market Perform at Bernstein... C.H. Robinson (CHRW) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Outperform from Neutral at Macquarie... HCC Insurance (HCC) upgraded at Raymond James... Hannon Armstrong (HASI) upgraded to Buy from Neutral at BofA/Merrill... Jamba (JMBA) upgraded to Outperform from Neutral at Wedbush... Midway Gold (MDW) upgraded to Speculative Buy from Hold at Canaccord... PG&E (PCG) upgraded to Buy from Hold at Deutsche Bank... RWE AG (RWEOY) upgraded to Neutral from Underweight at JPMorgan... Starwood (HOT) upgraded to Buy from Hold at Craig-Hallum... Total System (TSS) upgraded to Overweight from Equal Weight at Stephens.
09:31 EDTABTAbbott acquires Topera
Subscribe for More Information
07:22 EDTABTAbbott upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
06:55 EDTABTAbbott upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
October 28, 2014
07:50 EDTABTAbbott management to meet with Deutsche Bank
Subscribe for More Information
October 23, 2014
06:22 EDTABTMylan, Abbott enter into amendment, still see deal closing in 1Q15
Subscribe for More Information
October 22, 2014
09:24 EDTABTAbbott says on track for another year of double digit adjusted EPS growth
Subscribe for More Information
09:21 EDTABTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
09:16 EDTABTAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
09:14 EDTABTAbbott sees FY14 operational sales growth in the mid single digits
Sees foreign exchange to have negative impact of approx. 2% on FY reported sales, somewhat more negative than previous expectations. Sees FY14 reported sales growth in low to mid single digits. Sees FY gross margin ratio about 55% of sales. Comments made on the Q3 earnings conference call.
08:04 EDTABTAbbott raises FY14 adjusted EPS view to $2.25-$2.27 from $2.19-$2.29
Subscribe for More Information
07:37 EDTABTAbbott sees Q4 EPS excl items 68c-70c, consensus 70c
Subscribe for More Information
07:36 EDTABTAbbott reports Q3 Nutrition revenue $1.79B, Q3 Diagnostics revenue $1.19B
Subscribe for More Information
07:34 EDTABTAbbott reports Q3 EPS 62c, consensus 59c
Subscribe for More Information
October 21, 2014
15:35 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
07:44 EDTABTAbbott volatility elevated into Q3 and outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use